eLichens Raises EUR 7 Million to Boost its Growth in France and Internationally
Designer of patented gas sensors and the first comprehensive air quality analysis and prediction platform, eLichens today announced a new EUR 7 million capital increase with its historical investors and two new entrants. This operation, which follows the success of the first raising of capital of over 4 million euros in July 2016, aims to market large volumes of its micro gas sensors to serve the needs of its industrial customers as well as the large-scale deployment of its platform that performs intelligent indoor and outdoor air quality analysis for the smart city, smart home and smart building markets.
The eLichens team relies on patented technologies developed jointly with renowned laboratories such as CEA-Leti and MIT.
In addition to the renewed and strengthened support from current shareholders, including DEMETER, SOFIMAC Innovation, Business Angels networks (members of France Angels) and Aereco, eLichens is delighted to welcome the Fonds Ville de Demain managed by Bpifrance as part of the Future Investment Program and BNP Paribas Développement.
The success of the fundraising reflects the interest and confidence of investors in the company, reinforced by the recent signing of production contracts with major international industrial groups. They wish to capitalize on eLichens' solutions to develop products in the field of worker safety as well as the implementation of urban scenarios to improve air quality in the city of tomorrow. With its unique and proprietary technology platform of indoor/outdoor stations incorporating artificial intelligence, eLichens addresses the markets for urban gas leak detection and analysis and residential and building energy efficiency.
"I am both delighted and proud of the significant progress made within eLichens, which is reflected in the growing attractiveness of our complete range of products, from patented gas sensors to integrated systems, to major industrial groups. The new fundraising initiative demonstrates the confidence shown in the strong potential of our company by historical shareholders and new entrants", says Wahid Issa, CEO of eLichens.
"Since 2016, the eLichens team has demonstrated its strong ability to develop highly innovative air quality analysis and prediction products and solutions. The contracts signed with major customers, in France and internationally, in a wide variety of business sectors confirm the relevance of the solution developed by the company. We are therefore delighted to continue supporting eLichens in this new phase of growth", explains Olivier Bordelanne, Investment Director at DEMETER.
"We are pleased to reiterate our confidence and strengthen our investment in eLichens. The founders brought together some world-renowned advisors and a very talented team. They have kept their promises and eLichens is well equipped to push the benefits of their disruptive sensor technologies and software solutions into the markets for air quality analysis and gas detection. By contributing to more than a third in this new round of funding, Sofimac Innovation is showing its resolve to significantly support companies that started 12 to 18 months earlier, so as to facilitate their international development ambitions", says Nicolas Boulay, Associate Director at SOFIMAC Innovation.
"Air quality, inside and outside our living spaces, is a major health issue. eLichens has developed unique sensor technologies and software to address the air quality market and make their deployment possible. The company has a strong team that has demonstrated its ability to convince several global players of the value of its products. The Fonds Ville de Demain is very happy to support eLichens in its development ambitions", states Laure Michel, Investment Director at Bpifrance.
"Business Angels, members of the France Angels network, have accompanied eLichens since its creation and have mobilized to support its development. This new phase, which Business Angels are supporting, aims to give concrete expression to the worldwide success of an innovative technology with an experienced team in a rapidly developing and vital market, namely that of air quality," says Pascal Péru, Business Angels representative for the eLichens project.
About eLichens ( www.elichens.com )
Created in December 2014, eLichens is a start-up with a mission to help individuals digitize their environment. The company relies on a portfolio of patents, know-how and skills, which enable it to develop and market complete sensor/data/services solutions to address the industrial, smart city and consumer markets. eLichens has its headquarters in Grenoble and offices in California.
About Demeter ( www.demeter-im.com ) :
Demeter is a major European private equity player in the field of energy and ecological transition. Its funds invest amounts from EUR 500,000 to EUR 30 million to support companies in the sector at all stages of their development: innovative start-ups, SMEs, fast-growing ETIs and infrastructure projects. Demeter's team comprises 33 staff based in Paris, Grenoble, Metz, Madrid. The company manages EUR 1,000 million and has made 120 investments over the past 12 years.
The EMERTEC 5 fund, an investor in eLichens, is dedicated to providing seed financing to innovative technology companies. The fund, endowed with a little more than EUR 50 million, was raised with the support of the Fonds National d’Amorçage (FNA). The latter is managed by Bpifrance Investissement within the framework of the Future Investment Program and the European Investment Fund (EIF) through the European Union Framework Program for Competitiveness and Innovation (CIP).
About Sofimac Innovation ( www.sofimacpartners.fr/innovation/)
Sofimac Innovation is an independent management company certified by the financial markets regulator (AMF) and dedicated to technological and innovative investment. We are present in Paris, Lyon, Rennes and Aix-en-Provence, as close as possible to the major innovation centers in France. We support innovative start-ups in their growth projects with a wide range of investment vehicles. Working in a wide variety of technological sectors, particularly in the health and digital sectors, our team comprises 10 experienced investor-entrepreneurs specialized in their field. The funds managed by Sofimac Innovation are subscribed by some of the most prestigious public and private institutional investors. Sofimac Innovation currently manages eight funds comprising around 80 active companies.
Sofimac Innovation, together with Sofimac Régions, forms part of the Sofimac Investment Managers group, which has been investing in innovation and growth capital for nearly 40 years. Sofimac IM teams are spread over eight national and regional locations.
About the Future Investment Program
With a budget of EUR 57 billion, the Future Investment Program (Programme d'Investissements d'Avenir – PIA), led by the General Secretariat for Investment, was set up by the French state to finance innovative and promising investments in the country. Six national priorities have thus been identified to enable France to increase its growth and employment potential:
- higher education, research and training,
- the commercialization of research and its transfer to the economic world,
- sustainable development,
- industry and SMEs,
- the digital economy,
- health and biotechnology.
Find out more about future investments: http://www.gouvernement.fr/secretariat-general-pour-l-investissement-sgpi – Twitter : @SGPI_avenir
Endowed with EUR 50 million, the VDD fund, managed by Bpifrance within the framework of the Future Investment Program, provides seed and venture capital to companies that develop technologies and services in the field of the smart city. The VDD fund may invest in start-up companies. The investments are made at the time of the first capital openings and can reach EUR 2 million. The companies targeted develop technological or commercial innovations or provide innovative services.
Bpifrance Investissement invests its equity capital through Bpifrance Investissement. Bpifrance finances companies – at every stage of their development – with loans, guarantees and equity. Bpifrance supports them in their innovation projects and internationally. Bpifrance also ensures their export activity through a wide range of products. Consulting, university, networking and acceleration programs for startups, SMEs and ETIs are also part of the offer for entrepreneurs.
Thanks to Bpifrance and its 48 regional offices, entrepreneurs enjoy the services of a close-by, single and efficient point of contact to help them face their challenges.
About BNP Paribas Développement
BNP Paribas Développement, a subsidiary of the BNP Paribas Group, is a public limited company created in 1988 and which invests its own funds directly to support the development of high-performing SMEs and ETIs and to ensure their sustainability by facilitating their transfer as minority shareholders. In addition to the financial resources made available to the company to ensure stable resources, the mission of BNP Paribas Développement is to support the management team in carrying out its medium-term strategic project. Our minority position ensures our partners appropriate governance without interference in day-to-day management, while benefiting from the strength of a recognized group and the experience of a partner with a portfolio of over 300 investments. The investment from our own funds guarantees our partners the option of long-term support, adapted to the project and enabling intermediate operations to be carried out: reorganization of capital, external growth, etc. In 2016, BNP Paribas Développement created a structure dedicated to innovation capital which invests in seed capital and in subsequent rounds to support the growth of start-ups with potential.
Find out more at www.bnpparibasdeveloppement.com/
About the Business Angels networks
The Business Angels networks, members of France Angels, are made up of natural persons. The Business Angel invests part of its assets in innovative companies, which also makes its skills, experience, relational networks and part of its time freely available to the company. The Business Angels networks that have participated in supporting eLichens are:
- Angels’ Bay Invest (ABI): network of Business Angels for the Côte d’Azur and Monaco (www.angelsbay.net)
- Business Angels des Grandes Ecoles (BADGE): network of Business Angels for the Grandes Ecoles (https://accueil.business-angels.info/).
- Femmes Business Angels (FBA): women's network of Business Angels (www.femmesbusinessangels.org).
- Grenoble Angels (GA): Association of Business Angels, Grenoble (www.grenoble-angels.com).
- Paris Business Angels (PBA): Paris network of Business Angels which invests throughout France (www.parisbusinessangels.com).
The original source-language text of this announcement is the official, authoritative version. Translations are provided as an accommodation only, and should be cross-referenced with the source-language text, which is the only version of the text intended to have legal effect.
Wahid Issa, +33 (0)6 47 71 01 30
Olivier Bordelanne, +33 (0)6 84 31 71 68
Nicolas Boulay, +33 (0)1 45 01 46 46
Bruno Arabian, +33 (0)6 87 88 47 26
Nicolas Jehly, +33 (0)1 41 79 95 12
Vincent Deshayes, +33 (0)6 98 60 55 61
BNP Paribas Développement
Anne Toupé, +33 (0)1 40 14 22 70
Director of Investments
Olivier Durbize, +33 (0)1 40 14 66 28
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Positive Trial Results with Filgotinib in Psoriatic Arthritis and Ankylosing Spondylitis Both Published in The Lancet22.10.2018 17:15 | Pressemelding
Gilead Sciences, Inc. (Nasdaq: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced that detailed results from two clinical trials evaluating filgotinib, an investigational, selective JAK1 inhibitor, for the treatment of psoriatic arthritis and ankylosing spondylitis were both published in The Lancet. The publication of the Phase 2 EQUATOR data also coincides with a plenary session presentation at the 2018 American College of Rheumatology/Association of Rheumatology Health Professionals (ACR/ARHP) Annual Meeting. “The results of the EQUATOR and TORTUGA studies demonstrate that filgotinib improved the signs and symptoms of patients with psoriatic arthritis whose disease had not responded to prior therapies and independently, for those with ankylosing spondylitis,” said John McHutchison, AO, MD, Chief Scientific Officer and Head of Research and Development, Gilead Sciences. “These findings represent an important step forward in our efforts to improve outcomes for people livin
First Data Polska Deploys Inside Secure’s Mobile Payment Technology To Securely and Easily Connect to Mastercard and Visa22.10.2018 15:36 | Pressemelding
Regulatory News: Inside Secure (Paris:INSD) (Euronext Paris: INSD), at the heart of security solutions for mobile and connected devices, today announced that First Data Polska S.A., a division of the global leader in commerce-enabling technology, selected Inside Secure technology to enable secure and flexible connections to Mastercard and Visa. First Data Polska S.A. chose Inside Secure’s Mobile Payment Client to easily integrate their solution with the Visa Token Service (VTS) and Mastercard Digital Enablement Service (MDES) – today’s major tokenization services that convert sensitive data into unique tokens that allow mobile payments to be processed. “Security and reliability are continual requirements for our services,” said Jolanta Rycerz, Member of Management Board at First Data Polska S.A. “We see Inside Secure as a valuable technology provider that enables us to easily migrate to the latest mobile payment technology and security standards. Thanks to Inside Secure, our customers,
PMI Launches Search for Next President and CEO22.10.2018 14:00 | Pressemelding
Project Management Institute (PMI), the world’s leading professional membership organization for project managers, announced today that it has retained Heidrick & Struggles to help the organization find its next President and Chief Executive Officer (CEO). The dynamic leader shall oversee the implementation of a new strategic plan and guide the organization toward a future designed to help thousands of project professionals around the world accelerate their careers and make ideas a reality. Heidrick & Struggles is a premier provider of executive search, leadership assessment and development, organization and team effectiveness, and culture shaping services globally. PMI will conduct a comprehensive global review of both internal and external candidates for this key position. The selected candidate will embody PMI’s core values and possess the skillsets necessary to advance the organization’s key goals. PMI’s next President and CEO will help it execute a bold new multi-year initiative d
E2open to Acquire INTTRA, Adding the World’s Leading Ocean Shipping Network and Software Provider, Creating an Integrated Global Supply Chain and Logistics Operating Network22.10.2018 13:43 | Pressemelding
E2open, the one place in the cloud to run your supply chain, today announced the acquisition of INTTRA, the leading ocean shipping network, software and information provider. The combination of INTTRA’s ocean carrier and shipper network with E2open’s industry leading business network will create a unified global logistics and supply chain network. E2open and INTTRA will join efforts to strengthen the connections and streamline the information flow between manufacturers, suppliers, shipping service providers, ocean carriers and all the participants in global trade. E2open is the largest cloud-based provider of networked supply chain solutions, featuring a complete portfolio of applications that enable the world’s most complex supply chains to better plan, collaborate, and execute their end-to-end operations. More than 70,000 partner companies and 200,000 users, many of the biggest brands and manufacturers across a range of industries, use the E2open network and platform to orchestrate t
Patient-Data Platform Raremark Raises £3m to Enable Precision Medicine in Rare Disease22.10.2018 12:00 | Pressemelding
Raremark, the leading patient-data platform in rare disease, has raised £3m in funding from investors, led by AlbionVC and Ananda Ventures, with participation from Oltre Venture and from existing major investor the Cass Entrepreneurship Fund. The funding will be used to develop Raremark’s patient-engagement and data-analysis technology, helping biopharmaceutical companies to identify, engage and learn from patients, accelerating the development of new treatments. Raremark’s platform is the foundation for building research networks of rare disease patients and their families. Raremark provides biopharmaceutical companies with access to anonymized and aggregated patient data, helping to reduce the time and cost of clinical development. The Raremark platform engages and retains patients, leveraging machine-learning technologies in novel ways. The approach is designed to raise health literacy and informed participation in medical research, to improve the quality of existing therapies and t
Celltrion Healthcare Hosts Forum with Patient Advocacy Groups to Provide Information on the Use of Biosimilars in Oncology22.10.2018 11:50 | Pressemelding
To coincide with the ESMO 2018 Congress in Munich, Germany, Celltrion Healthcare invited perspective from experts including a physician and pharmacist to provide information to patient advocacy groups on the history of biosimilars, how they are tested and approved, their cost saving benefit and the wealth of clinical evidence already available on their use in order to improve understanding of biosimilars. The introduction of biosimilars in the treatment of cancer has the potential to reduce pressure on healthcare budgets and increase access to other innovative treatments or more potent regimens. This is achieved by offering more cost-effective alternatives to the reference medicinal products and by increasing competition in the market. Breast cancer is the most common cancer in women worldwide and accounts for a quarter of all cancer diagnoses in women.1 For the benefits of biosimilar use to be realised in oncology, and in the treatment of breast cancer, barriers to their uptake need t